[
  {
    "ts": null,
    "headline": "Stock Market Today: Indexes Up In Strong Week On Trump News; Oracle Dives (Live Coverage)",
    "summary": "The Dow Jones Industrial Average and other key indexes wrapped up the week on a high note after President Donald Trump's latest tariff update Friday eased the worst fears for investors. Dow component American Express shot up, flexing technical strength, while a regional bank's earnings assuaged some lending concerns on the stock market today.",
    "url": "https://finnhub.io/api/news?id=facaa86b3c6f1fc0d2b94a0fb71f82137216dfcc0778eaa46592039d982ccba4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760733482,
      "headline": "Stock Market Today: Indexes Up In Strong Week On Trump News; Oracle Dives (Live Coverage)",
      "id": 137162634,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The Dow Jones Industrial Average and other key indexes wrapped up the week on a high note after President Donald Trump's latest tariff update Friday eased the worst fears for investors. Dow component American Express shot up, flexing technical strength, while a regional bank's earnings assuaged some lending concerns on the stock market today.",
      "url": "https://finnhub.io/api/news?id=facaa86b3c6f1fc0d2b94a0fb71f82137216dfcc0778eaa46592039d982ccba4"
    }
  },
  {
    "ts": null,
    "headline": "These Stocks Moved the Most Today: Zions Bancorp, Jefferies, Amex, Oracle, Novo Nordisk, Lilly, State Street, CSX, and More",
    "summary": "Zions Bancorp trades higher following a drop of 13% in the previous session on bank loan worries, while American Express rises after posting better-than-expected earnings.",
    "url": "https://finnhub.io/api/news?id=a26effb853365016c2fbcf48968ddd5f5a0f94d6a0d85c8ee7d78abfa59dc369",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760732700,
      "headline": "These Stocks Moved the Most Today: Zions Bancorp, Jefferies, Amex, Oracle, Novo Nordisk, Lilly, State Street, CSX, and More",
      "id": 137162636,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Zions Bancorp trades higher following a drop of 13% in the previous session on bank loan worries, while American Express rises after posting better-than-expected earnings.",
      "url": "https://finnhub.io/api/news?id=a26effb853365016c2fbcf48968ddd5f5a0f94d6a0d85c8ee7d78abfa59dc369"
    }
  },
  {
    "ts": null,
    "headline": "Why Eli Lilly (LLY) Stock Is Down Today",
    "summary": "Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) fell 3.5% in the afternoon session after political comments introduced significant uncertainty regarding the future pricing of the company’s weight-loss and diabetes drugs, Zepbound and Mounjaro.",
    "url": "https://finnhub.io/api/news?id=3f3ddef8097d0ba7389427540a375f6371f96245e2906876448f68e3acdc5a37",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760723443,
      "headline": "Why Eli Lilly (LLY) Stock Is Down Today",
      "id": 137128251,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) fell 3.5% in the afternoon session after political comments introduced significant uncertainty regarding the future pricing of the company’s weight-loss and diabetes drugs, Zepbound and Mounjaro.",
      "url": "https://finnhub.io/api/news?id=3f3ddef8097d0ba7389427540a375f6371f96245e2906876448f68e3acdc5a37"
    }
  },
  {
    "ts": null,
    "headline": "Trump Pledges To Cut Obesity Drug Prices. Novo Nordisk, Eli Lilly Stocks Dive.",
    "summary": "Novo Nordisk and Eli Lilly stocks slumped Friday after President Donald Trump said he would cut the price of weight-loss drugs.",
    "url": "https://finnhub.io/api/news?id=e519e9e7b173c4bd643bcd499e29d2012fa5f03dfba9746c657fddc52f2f1b59",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760715590,
      "headline": "Trump Pledges To Cut Obesity Drug Prices. Novo Nordisk, Eli Lilly Stocks Dive.",
      "id": 137126998,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo Nordisk and Eli Lilly stocks slumped Friday after President Donald Trump said he would cut the price of weight-loss drugs.",
      "url": "https://finnhub.io/api/news?id=e519e9e7b173c4bd643bcd499e29d2012fa5f03dfba9746c657fddc52f2f1b59"
    }
  },
  {
    "ts": null,
    "headline": "Stock Market Today: Indexes Higher In Strong Week On Trump News; Oracle Dives (Live Coverage)",
    "summary": "Stock Market Today: Indexes Higher In Strong Week On Trump News; Oracle Dives (Live Coverage)",
    "url": "https://finnhub.io/api/news?id=3fab94809be5570c19ca8786c14fc3ef079f5d204f1214565f4512accdaf10af",
    "source": "DowJones",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760719082,
      "headline": "Stock Market Today: Indexes Higher In Strong Week On Trump News; Oracle Dives (Live Coverage)",
      "id": 137136349,
      "image": "",
      "related": "LLY",
      "source": "DowJones",
      "summary": "Stock Market Today: Indexes Higher In Strong Week On Trump News; Oracle Dives (Live Coverage)",
      "url": "https://finnhub.io/api/news?id=3fab94809be5570c19ca8786c14fc3ef079f5d204f1214565f4512accdaf10af"
    }
  },
  {
    "ts": null,
    "headline": "Top Stock Movers Now: Kenvue, American Express, Truist, Newmont, and More",
    "summary": "Major U.S. equities indexes climbed at midday Friday as regional bank stocks rebounded after a flurry of corporate earnings reports.",
    "url": "https://finnhub.io/api/news?id=75fb429d9978e2887b874b0dfc45d973a8ddf8b0bf52c83d88c86b0ae3d7c17d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760718493,
      "headline": "Top Stock Movers Now: Kenvue, American Express, Truist, Newmont, and More",
      "id": 137127502,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Major U.S. equities indexes climbed at midday Friday as regional bank stocks rebounded after a flurry of corporate earnings reports.",
      "url": "https://finnhub.io/api/news?id=75fb429d9978e2887b874b0dfc45d973a8ddf8b0bf52c83d88c86b0ae3d7c17d"
    }
  },
  {
    "ts": null,
    "headline": "3 Price Catalysts For Eli Lilly",
    "summary": "I go over 3 potential catalysts that could drive Eli Lilly's stock price up... or down. Read the full analysis here.",
    "url": "https://finnhub.io/api/news?id=3084c73fd3836a539b5dae26c559828ff74a321f7ecc65300f09e602dacc2dec",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760718383,
      "headline": "3 Price Catalysts For Eli Lilly",
      "id": 137129254,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1414474713/image_1414474713.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "I go over 3 potential catalysts that could drive Eli Lilly's stock price up... or down. Read the full analysis here.",
      "url": "https://finnhub.io/api/news?id=3084c73fd3836a539b5dae26c559828ff74a321f7ecc65300f09e602dacc2dec"
    }
  },
  {
    "ts": null,
    "headline": "Is Trump Going to Kill the GLP-1 Cash Cow?",
    "summary": "The Boom That Built Billion-Dollar Empires GLP-1 drugs have reshaped the pharmaceutical landscape, turning obesity and diabetes treatments into massive revenue streams for Novo Nordisk (NYSE:NVO) and Eli Lilly (NYSE:LLY). These medications, including NVO’s Ozempic and Wegovy, and LLY’s Mounjaro and Zepbound, mimic hormones to curb appetite and regulate blood sugar. Their popularity exploded in ... Is Trump Going to Kill the GLP-1 Cash Cow?",
    "url": "https://finnhub.io/api/news?id=a9a1e7d870bcfa7ee8233d898606d98d6d030028947b4ca530d8d4023a92c5be",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760717125,
      "headline": "Is Trump Going to Kill the GLP-1 Cash Cow?",
      "id": 137164122,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The Boom That Built Billion-Dollar Empires GLP-1 drugs have reshaped the pharmaceutical landscape, turning obesity and diabetes treatments into massive revenue streams for Novo Nordisk (NYSE:NVO) and Eli Lilly (NYSE:LLY). These medications, including NVO’s Ozempic and Wegovy, and LLY’s Mounjaro and Zepbound, mimic hormones to curb appetite and regulate blood sugar. Their popularity exploded in ... Is Trump Going to Kill the GLP-1 Cash Cow?",
      "url": "https://finnhub.io/api/news?id=a9a1e7d870bcfa7ee8233d898606d98d6d030028947b4ca530d8d4023a92c5be"
    }
  },
  {
    "ts": null,
    "headline": "NVO and LLY Stocks Slide as Trump Signals Price Cuts for GLP-1 Drugs",
    "summary": "Trump's pledge to slash GLP-1 drug prices sends Novo Nordisk and Eli Lilly shares tumbling, raising questions about the feasibility of such a development.",
    "url": "https://finnhub.io/api/news?id=2b37262ade52239d363ce8f747011f583a94e1c13caa378de668b7764b146b65",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760715840,
      "headline": "NVO and LLY Stocks Slide as Trump Signals Price Cuts for GLP-1 Drugs",
      "id": 137127503,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Trump's pledge to slash GLP-1 drug prices sends Novo Nordisk and Eli Lilly shares tumbling, raising questions about the feasibility of such a development.",
      "url": "https://finnhub.io/api/news?id=2b37262ade52239d363ce8f747011f583a94e1c13caa378de668b7764b146b65"
    }
  },
  {
    "ts": null,
    "headline": "Here's What Trump Said That's Pressuring Novo Nordisk and Eli Lilly Stocks",
    "summary": "President Trump said he would lower the prices of popular weight-loss drugs, pressuring shares of drugmakers Novo Nordisk and Eli Lilly Friday.",
    "url": "https://finnhub.io/api/news?id=764c11b6040ae68d3cae4350495af218b2bdc2e0a8568abe376fdeec994a8b5e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760713739,
      "headline": "Here's What Trump Said That's Pressuring Novo Nordisk and Eli Lilly Stocks",
      "id": 137127000,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "President Trump said he would lower the prices of popular weight-loss drugs, pressuring shares of drugmakers Novo Nordisk and Eli Lilly Friday.",
      "url": "https://finnhub.io/api/news?id=764c11b6040ae68d3cae4350495af218b2bdc2e0a8568abe376fdeec994a8b5e"
    }
  },
  {
    "ts": null,
    "headline": "Pharma Stocks Fall After Trump Says Ozempic Could Be Much Cheaper",
    "summary": "Shares of drugmakers Novo Nordisk and Eli Lilly fell Friday on concerns about pricing pressure after President Trump said the cost of blockbuster diabetes drug Ozempic, which is also used for weight loss, would come down significantly.  Novo Nordisk’s American depositary receipts fell about 4% and Lilly shares were off about 3%.  Trump said Thursday the out of pocket cost of Ozempic could fall to $150.",
    "url": "https://finnhub.io/api/news?id=69bf88422504df137388990a6a48708870947e1f820f4bd625550830039753b4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760713124,
      "headline": "Pharma Stocks Fall After Trump Says Ozempic Could Be Much Cheaper",
      "id": 137127505,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Shares of drugmakers Novo Nordisk and Eli Lilly fell Friday on concerns about pricing pressure after President Trump said the cost of blockbuster diabetes drug Ozempic, which is also used for weight loss, would come down significantly.  Novo Nordisk’s American depositary receipts fell about 4% and Lilly shares were off about 3%.  Trump said Thursday the out of pocket cost of Ozempic could fall to $150.",
      "url": "https://finnhub.io/api/news?id=69bf88422504df137388990a6a48708870947e1f820f4bd625550830039753b4"
    }
  },
  {
    "ts": null,
    "headline": "Stock Market Today: Dow Rebounds After Bank Scare; Eli Lilly, Novo Sell Off On Trump Comments (Live Coverage)",
    "summary": "Stock Market Today: The Dow Jones index rose Friday amid bank fears. Eli Lilly and Novo Nordisk tumbled on Trump comments.",
    "url": "https://finnhub.io/api/news?id=22ca20fb9126279eb9076ab9e1982c538f6c3b087af1c62912b7e6a6d423efa4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760712645,
      "headline": "Stock Market Today: Dow Rebounds After Bank Scare; Eli Lilly, Novo Sell Off On Trump Comments (Live Coverage)",
      "id": 137125531,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Stock Market Today: The Dow Jones index rose Friday amid bank fears. Eli Lilly and Novo Nordisk tumbled on Trump comments.",
      "url": "https://finnhub.io/api/news?id=22ca20fb9126279eb9076ab9e1982c538f6c3b087af1c62912b7e6a6d423efa4"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly, Novo Nordisk Stocks Drop. Trump Targets Ozempic, ‘Fat Loss’ Drug Prices.",
    "summary": "Trump told reporters late Thursday that the list price of Ozempic, which he called “the fat loss drug,” will be “much lower.”",
    "url": "https://finnhub.io/api/news?id=aac904129e1ae6d11fe4092374dd6bdba6c3d8f12a414aad8f867725c216d125",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760710560,
      "headline": "Eli Lilly, Novo Nordisk Stocks Drop. Trump Targets Ozempic, ‘Fat Loss’ Drug Prices.",
      "id": 137125639,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Trump told reporters late Thursday that the list price of Ozempic, which he called “the fat loss drug,” will be “much lower.”",
      "url": "https://finnhub.io/api/news?id=aac904129e1ae6d11fe4092374dd6bdba6c3d8f12a414aad8f867725c216d125"
    }
  },
  {
    "ts": null,
    "headline": "These Stocks Are Moving the Most Today: Zions Bancorp, Jefferies, Amex, Oracle, Novo Nordisk, Lilly, State Street, CSX, and More",
    "summary": "Zions Bancorp trades higher following a drop of 13% in the previous session on bank loan worries, while American Express rises after posting better-than-expected earnings.",
    "url": "https://finnhub.io/api/news?id=ba7ff24f2606ca4c177c6ec0b9e95b200ab6f33eafa00f9ba4976504ea1e2448",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760709180,
      "headline": "These Stocks Are Moving the Most Today: Zions Bancorp, Jefferies, Amex, Oracle, Novo Nordisk, Lilly, State Street, CSX, and More",
      "id": 137125640,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Zions Bancorp trades higher following a drop of 13% in the previous session on bank loan worries, while American Express rises after posting better-than-expected earnings.",
      "url": "https://finnhub.io/api/news?id=ba7ff24f2606ca4c177c6ec0b9e95b200ab6f33eafa00f9ba4976504ea1e2448"
    }
  },
  {
    "ts": null,
    "headline": "Trump says Ozempic will get cheaper. Novo Nordisk, Eli Lilly stock slump",
    "summary": "Trump’s comments on Ozempic “signal aggressive posturing” in drug price negotiations, an analyst said",
    "url": "https://finnhub.io/api/news?id=b176d1394617abe6995c34dd109a8951759f4a09bbeadc75d16a2d9d818e6c3f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760709124,
      "headline": "Trump says Ozempic will get cheaper. Novo Nordisk, Eli Lilly stock slump",
      "id": 137125641,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Trump’s comments on Ozempic “signal aggressive posturing” in drug price negotiations, an analyst said",
      "url": "https://finnhub.io/api/news?id=b176d1394617abe6995c34dd109a8951759f4a09bbeadc75d16a2d9d818e6c3f"
    }
  },
  {
    "ts": null,
    "headline": "Drugmakers slide on Trump comments, EssilorLuxottica's Meta glasses",
    "summary": "Morning Brief host Allie Canal tracks several of the day's top trending stock tickers, including shares of Eli Lilly (LLY) and Novo Nordisk (NVO) falling after President Trump said he expects to help ease GLP-1 drug prices lower, American Express (AXP) reporting record revenue in its third quarter earnings results, and EssilorLuxottica (EL.PA, ESLOY) stock rising to a record high boosted by the sale of Meta Platforms' (META) AI-powered Ray-Bans glasses. To watch more expert insights and analysis on the latest market action, check out more Morning Brief.",
    "url": "https://finnhub.io/api/news?id=f6a8b5624e0f03d1b84c9174482579998afe65953758b89efc53fd7491107f36",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760708205,
      "headline": "Drugmakers slide on Trump comments, EssilorLuxottica's Meta glasses",
      "id": 137125574,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Morning Brief host Allie Canal tracks several of the day's top trending stock tickers, including shares of Eli Lilly (LLY) and Novo Nordisk (NVO) falling after President Trump said he expects to help ease GLP-1 drug prices lower, American Express (AXP) reporting record revenue in its third quarter earnings results, and EssilorLuxottica (EL.PA, ESLOY) stock rising to a record high boosted by the sale of Meta Platforms' (META) AI-powered Ray-Bans glasses. To watch more expert insights and analysis on the latest market action, check out more Morning Brief.",
      "url": "https://finnhub.io/api/news?id=f6a8b5624e0f03d1b84c9174482579998afe65953758b89efc53fd7491107f36"
    }
  },
  {
    "ts": null,
    "headline": "Pre-Q3 Earnings: Is Viking Therapeutics Stock a Portfolio Must-Have?",
    "summary": "VKTX is likely to have headed into Q3 earnings with no product revenue, pipeline updates in focus and widening loss forecasts testing investor patience.",
    "url": "https://finnhub.io/api/news?id=caa4358bdb2d122c5031c9a0a0b7765caedc8cd55fc439ce263bdd3f00a6bb4b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760707800,
      "headline": "Pre-Q3 Earnings: Is Viking Therapeutics Stock a Portfolio Must-Have?",
      "id": 137126599,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "VKTX is likely to have headed into Q3 earnings with no product revenue, pipeline updates in focus and widening loss forecasts testing investor patience.",
      "url": "https://finnhub.io/api/news?id=caa4358bdb2d122c5031c9a0a0b7765caedc8cd55fc439ce263bdd3f00a6bb4b"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly, Novo Nordisk Tumbles After Trump Says Weight-Loss Drugs Are 'Too Expensive'",
    "summary": "Weight-Loss Drug Stocks Tumble as Trump Vows Massive Price Cuts",
    "url": "https://finnhub.io/api/news?id=1f4c53385c72bc7d01574a3997406bdd9a4094c035400e917da400d916f36b54",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760707404,
      "headline": "Eli Lilly, Novo Nordisk Tumbles After Trump Says Weight-Loss Drugs Are 'Too Expensive'",
      "id": 137125643,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Weight-Loss Drug Stocks Tumble as Trump Vows Massive Price Cuts",
      "url": "https://finnhub.io/api/news?id=1f4c53385c72bc7d01574a3997406bdd9a4094c035400e917da400d916f36b54"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Sets Ambitious Sustainability Goals Despite Headwinds",
    "summary": "Eli Lilly's prescription for growth and sustainability includes a strong drug pipeline, revenue growth and energy investments.",
    "url": "https://finnhub.io/api/news?id=fa4d45c192cbd719f7fa8b9faf662ed9490b5398375f0b48bffae053be2d48a8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760706092,
      "headline": "Eli Lilly Sets Ambitious Sustainability Goals Despite Headwinds",
      "id": 137125644,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly's prescription for growth and sustainability includes a strong drug pipeline, revenue growth and energy investments.",
      "url": "https://finnhub.io/api/news?id=fa4d45c192cbd719f7fa8b9faf662ed9490b5398375f0b48bffae053be2d48a8"
    }
  },
  {
    "ts": null,
    "headline": "5 Things to Know Before the Stock Market Opens",
    "summary": "News of the day for Oct. 17, 2025",
    "url": "https://finnhub.io/api/news?id=5e5844e73a34aaa163fd10e2008030831e56d3a3c4d8b8c2350edde7b9188f66",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760704503,
      "headline": "5 Things to Know Before the Stock Market Opens",
      "id": 137125645,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "News of the day for Oct. 17, 2025",
      "url": "https://finnhub.io/api/news?id=5e5844e73a34aaa163fd10e2008030831e56d3a3c4d8b8c2350edde7b9188f66"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Makes A Bold Claim For Its Biggest Cancer Drug",
    "summary": "Eli Lilly said Friday a combination using Verzenio reduced the risk of death by nearly 16% over two years for breast cancer patients.",
    "url": "https://finnhub.io/api/news?id=c41501419c9e0db9a332890dfa6d82ac9daa638b99405b651711e79548eb33d7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760702420,
      "headline": "Eli Lilly Makes A Bold Claim For Its Biggest Cancer Drug",
      "id": 137125646,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly said Friday a combination using Verzenio reduced the risk of death by nearly 16% over two years for breast cancer patients.",
      "url": "https://finnhub.io/api/news?id=c41501419c9e0db9a332890dfa6d82ac9daa638b99405b651711e79548eb33d7"
    }
  },
  {
    "ts": null,
    "headline": "Lilly's Verzenio® (abemaciclib) prolonged survival in HR+, HER2-, high-risk early breast cancer with two years of treatment",
    "summary": "Eli Lilly and Company (NYSE: LLY) today announced results from the primary overall survival (OS) analysis of the Phase 3 monarchE trial showing that two years of adjuvant Verzenio plus endocrine therapy (ET) reduced the risk of death by 15.8% versus ET alone and resulted in sustained long-term improvements in invasive disease-free survival (IDFS) and distant relapse-free survival (DRFS), in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-),",
    "url": "https://finnhub.io/api/news?id=93a595984a33ff2d726caae0d588538cce867e754f917a4d72ffc4b62850046d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760702400,
      "headline": "Lilly's Verzenio® (abemaciclib) prolonged survival in HR+, HER2-, high-risk early breast cancer with two years of treatment",
      "id": 137125647,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE: LLY) today announced results from the primary overall survival (OS) analysis of the Phase 3 monarchE trial showing that two years of adjuvant Verzenio plus endocrine therapy (ET) reduced the risk of death by 15.8% versus ET alone and resulted in sustained long-term improvements in invasive disease-free survival (IDFS) and distant relapse-free survival (DRFS), in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-),",
      "url": "https://finnhub.io/api/news?id=93a595984a33ff2d726caae0d588538cce867e754f917a4d72ffc4b62850046d"
    }
  },
  {
    "ts": null,
    "headline": "Lilly, Novo Slide as Trump Touts 'Much Lower' Ozempic Price",
    "summary": "President Donald Trump said the price of the diabetes drug Ozempic will soon be \"much lower\" and could come down to just $150 a month, pushing shares of Novo Nordisk A/S and Eli Lilly & Co. lower. Sam Fazeli of Bloomberg Intelligence has more.",
    "url": "https://finnhub.io/api/news?id=76e3b34acb45a4234601ae9e74f09803ec89a2a20565a343c191e17b5d96c394",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760696679,
      "headline": "Lilly, Novo Slide as Trump Touts 'Much Lower' Ozempic Price",
      "id": 137125648,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "President Donald Trump said the price of the diabetes drug Ozempic will soon be \"much lower\" and could come down to just $150 a month, pushing shares of Novo Nordisk A/S and Eli Lilly & Co. lower. Sam Fazeli of Bloomberg Intelligence has more.",
      "url": "https://finnhub.io/api/news?id=76e3b34acb45a4234601ae9e74f09803ec89a2a20565a343c191e17b5d96c394"
    }
  },
  {
    "ts": null,
    "headline": "The Zacks Analyst Blog Highlights Eli Lilly, Novo Nordisk, Amgen and Viking Therapeutics",
    "summary": "Eli Lilly's blockbuster GLP-1 drugs, Mounjaro and Zepbound, are driving explosive growth as the company prepares to report Q3 results.",
    "url": "https://finnhub.io/api/news?id=85c65f5784f3f16a210fe2ddcd312f564b27436e83907158d1cef050de7fdd15",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760696520,
      "headline": "The Zacks Analyst Blog Highlights Eli Lilly, Novo Nordisk, Amgen and Viking Therapeutics",
      "id": 137125649,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly's blockbuster GLP-1 drugs, Mounjaro and Zepbound, are driving explosive growth as the company prepares to report Q3 results.",
      "url": "https://finnhub.io/api/news?id=85c65f5784f3f16a210fe2ddcd312f564b27436e83907158d1cef050de7fdd15"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly vs. Viking Therapeutics Stock: Which Is the Best Growth Opportunity, According to Wall Street?",
    "summary": "These stocks have climbed in the triple digits over the past few years.",
    "url": "https://finnhub.io/api/news?id=a3aeb9f0bf35aced6921f94c6ace95270b2ab8d2cd1bf04bc1c033dde7c4873d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760688900,
      "headline": "Eli Lilly vs. Viking Therapeutics Stock: Which Is the Best Growth Opportunity, According to Wall Street?",
      "id": 137121699,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "These stocks have climbed in the triple digits over the past few years.",
      "url": "https://finnhub.io/api/news?id=a3aeb9f0bf35aced6921f94c6ace95270b2ab8d2cd1bf04bc1c033dde7c4873d"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk falls on Trump threat to lower Ozempic prices and other morning movers",
    "summary": "Novo Nordisk falls on Trump threat to lower Ozempic prices and other morning movers",
    "url": "https://finnhub.io/api/news?id=aa9852290b011c063022aa5287196e6dfdca1488bab76c97ea159e12537befca",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760686551,
      "headline": "Novo Nordisk falls on Trump threat to lower Ozempic prices and other morning movers",
      "id": 137136371,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Novo Nordisk falls on Trump threat to lower Ozempic prices and other morning movers",
      "url": "https://finnhub.io/api/news?id=aa9852290b011c063022aa5287196e6dfdca1488bab76c97ea159e12537befca"
    }
  },
  {
    "ts": null,
    "headline": "Novo, Lilly Fall as Trump Touts ‘Much Lower’ Ozempic Price",
    "summary": "The US list price of Ozempic, which Trump called “the fat loss drug,” is roughly $1,000 for a month’s supply.  Trump told reporters on Thursday that the cost of the drug, made by Novo, will soon be “much lower.”  Lilly sells similar treatments, including Mounjaro and Zepbound.",
    "url": "https://finnhub.io/api/news?id=35d78233bb50e2071e72a7b62c3b012429afda8e9bb51b31e8d168485bbb5ecd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760686279,
      "headline": "Novo, Lilly Fall as Trump Touts ‘Much Lower’ Ozempic Price",
      "id": 137121700,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The US list price of Ozempic, which Trump called “the fat loss drug,” is roughly $1,000 for a month’s supply.  Trump told reporters on Thursday that the cost of the drug, made by Novo, will soon be “much lower.”  Lilly sells similar treatments, including Mounjaro and Zepbound.",
      "url": "https://finnhub.io/api/news?id=35d78233bb50e2071e72a7b62c3b012429afda8e9bb51b31e8d168485bbb5ecd"
    }
  },
  {
    "ts": null,
    "headline": "Wall Street Breakfast Podcast: Regional Bank Worries Drag Futures Lower",
    "summary": "Stock index futures slump as concerns on health of banks rattle sentiments. Novo Nordisk, Eli Lilly slide after Trump pledges 'much lower' Ozempic price. Ford to recall nearly 625K vehicles.",
    "url": "https://finnhub.io/api/news?id=a844a41c95214e806d5cecad417e671a3f431d2ac13d6128f27a2accde7e791f",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760683319,
      "headline": "Wall Street Breakfast Podcast: Regional Bank Worries Drag Futures Lower",
      "id": 137124597,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2158117337/image_2158117337.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Stock index futures slump as concerns on health of banks rattle sentiments. Novo Nordisk, Eli Lilly slide after Trump pledges 'much lower' Ozempic price. Ford to recall nearly 625K vehicles.",
      "url": "https://finnhub.io/api/news?id=a844a41c95214e806d5cecad417e671a3f431d2ac13d6128f27a2accde7e791f"
    }
  },
  {
    "ts": null,
    "headline": "Weight-loss drug stocks are tumbling after Trump promised their costs ‘will be much lower’",
    "summary": "Weight-loss drug stocks are tumbling after Trump promised their costs ‘will be much lower’",
    "url": "https://finnhub.io/api/news?id=4ba1b203fdf8076781029284e74f3a67c1750818186e57d3f525d51dad162ffe",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760681100,
      "headline": "Weight-loss drug stocks are tumbling after Trump promised their costs ‘will be much lower’",
      "id": 137136372,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Weight-loss drug stocks are tumbling after Trump promised their costs ‘will be much lower’",
      "url": "https://finnhub.io/api/news?id=4ba1b203fdf8076781029284e74f3a67c1750818186e57d3f525d51dad162ffe"
    }
  }
]